Related Experiment Video

Updated: Aug 4, 2026

LC-MS Analysis of Human Platelets as a Platform for Studying Mitochondrial Metabolism
06:04

LC-MS Analysis of Human Platelets as a Platform for Studying Mitochondrial Metabolism

Published on: April 4, 2016

Reduced platelet monoamine oxidase activity in a subgroup of schizophrenic patients

J J Schildkraut, J M Herzog, P J Orsulak

    The American Journal of Psychiatry
    |April 1, 1976
    PubMed

    Insights

    Reduced platelet monoamine oxidase (MAO) activity was observed in paranoid schizophrenic patients with hallucinations and delusions. This finding indicates that low MAO activity is specific to a clinically identifiable subgroup of schizophrenia patients.

    Area of Science:

    • Neuroscience
    • Psychiatry
    • Biochemistry

    Background:

    • Schizophrenia is a complex psychiatric disorder with varied clinical presentations.
    • Platelet monoamine oxidase (MAO) is an enzyme involved in neurotransmitter metabolism, and its activity has been investigated in psychiatric conditions.

    Purpose of the Study:

    • To investigate whether reduced platelet monoamine oxidase (MAO) activity is a consistent finding across all schizophrenia patients.
    • To identify if reduced platelet MAO activity is associated with specific clinical symptoms in schizophrenia.

    Main Methods:

    • Assessing platelet monoamine oxidase (MAO) activity in two distinct subgroups of schizophrenic patients.
    • Comparing MAO activity levels between schizophrenic subgroups and control groups.
    • Correlating MAO activity with the presence or absence of auditory hallucinations and delusions.

    Main Results:

    • Platelet MAO activity was significantly lower in a subgroup of 16 schizophrenic patients characterized by auditory hallucinations and delusions.
    • MAO activity was not reduced in a separate group of 16 schizophrenic patients lacking these specific symptoms.
    • These results suggest a specific association between reduced platelet MAO activity and particular psychotic features.

    Conclusions:

    • Reduced platelet monoamine oxidase (MAO) activity is not a universal biomarker for all schizophrenia patients.
    • Low platelet MAO activity appears to be linked to a clinically identifiable subgroup of schizophrenic individuals, particularly those experiencing hallucinations and delusions.
    • This finding may have implications for understanding the neurobiological heterogeneity of schizophrenia.

    More Related Videos

    A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices07:56

    A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

    Published on: August 11, 2021

    Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra05:14

    Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

    Published on: September 8, 2021

    Related Concept Videos

    Drugs Affecting Neurotransmitter Synthesis01:29

    Drugs Affecting Neurotransmitter Synthesis

    Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
    Psychosis and Antipsychotic Drugs: Overview01:28

    Psychosis and Antipsychotic Drugs: Overview

    The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
    Antidepressant Drugs: MAOIs and Other Agents01:23

    Antidepressant Drugs: MAOIs and Other Agents

    Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
    Negative and Cognitive Symptoms of Schizophrenia01:30

    Negative and Cognitive Symptoms of Schizophrenia

    Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
    Negative Symptoms
    Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
    Biological Causes of Schizophrenia01:29

    Biological Causes of Schizophrenia

    Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
    Genetic Factors in Schizophrenia
    The genetic basis of schizophrenia is strongly supported by family and twin studies.